Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Study Overview: Amgen Inc. is conducting a clinical ...

Opdivo and Yervoy improve cure rates in resected stage 3/4 melanoma compared to placebo, with Opdivo showing superior efficacy. CheckMate 238 and EORTC 18071 trials reveal Opdivo's cure rate advantage ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

AU-007, combined with Opdivo and low-dose aldesleukin, is being evaluated in a phase 2 cohort for second-line melanoma treatment. Previous trials showed AU-007's early antitumor activity and ...

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...

MADRID (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, ...

These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for official ESMO press conference At ten years, more than 40% (43%) of patients ...

H.C. Wainwright upgraded Replimune (REPL) to Buy from Neutral with a $12 price target after the company resubmitted the biologics license ...

Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives ...

Different parts of Medicare can provide coverage for cancer treatments, including Opdivo. The coverage will depend on various factors, such as the phase of treatment and where a person receives ...

An investigational treatment, used in combination with another cancer medication, took an important step forward after ...